Skip to Main Content

Editors note: A recording of the conversation is embedded below.

Sponsored By
 

Every week, STAT+ subscribers get access to exclusive conversations with biotech, pharma, and health tech leaders. This week, STAT senior biotech writer Adam Feuerstein will be joined by Paul Matteis, managing director and biotechnology analyst at Stifel. They will be discussing updates and impacts of current central nervous system drug development, and of course be taking your questions live.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED